We harness cell-to-cell communication to create new diagnostics for human diseases.

Listening to cellular messaging to empower healthcare

The promise of personalized healthcare rests on precise disease biosignatures.

EV-HIV for point-of-care screening

Our lead infectious disease program harnesses extracellular vesicles (EVs) to be the first non-laboratory test to cover all stages of HIV infection.

EV-PSA for prostate cancer screening

Our EV-PSA prostate cancer screening test has the potential to dramatically increase the diagnostic predictivity of PSA to discriminate between benign and malignant conditions.


Our proprietary platform harnesses the unique communication in extracellular vesicle (EV) proteins, nucleic acids, and lipids for simple, point-of-care tests.

We use the platform for our pipeline and to partner with others on their proprietary tests for infectious disease, immune and metabolic monitoring, and cancer.